Agios Pharmaceuticals Files Form 8-K: Regulation FD Disclosure on PYRUKYND and Regulatory Update in Saudi Arabia

Agios Pharmaceuticals, Inc. has filed a Form 8-K with the U.S. Securities and Exchange Commission on August 4, 2025, disclosing significant information regarding PYRUKYND, a treatment for rare diseases. The report addresses recent data from the U.S. Food and Drug Administration's Adverse Event Reporting System, received in connection with a Freedom of Information Act request. Patient safety remains paramount, and Agios has robust pharmacovigilance practices in place to monitor and report safety information. The company's established benefit-risk profile for PYRUKYND has not been altered by the available information, and Agios will continue to follow its standard pharmacovigilance processes. Separately, the Saudi Food and Drug Authority has approved PYRUKYND for treating adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia.

Key Takeaways:

• Agios Pharmaceuticals, Inc. has filed Form 8-K with the U.S. Securities and Exchange Commission on August 4, 2025, in relation to PYRUKYND data from the U.S. FDA's Adverse Event Reporting System.
• Three out of four cases referenced in the Analyst Report were reported to Agios and subsequently to the FDA, as part of the company's standard pharmacovigilance practices.
• The cases involve patients with pyruvate kinase (PK) deficiency, sickle cell disease, and alpha- or beta-thalassemia, with various adverse events reported, including death and pulmonary embolism.
• Agios is evaluating the available information against the known safety profile of PYRUKYND and will continue to follow established pharmacovigilance processes.
• The company's benefit-risk profile for PYRUKYND has not been altered by the available data.
• The Saudi Food and Drug Authority has approved PYRUKYND for treating adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia.
• Agios is committed to delivering safe, effective treatments for patients with rare diseases.

Statistics:

• Four patient cases were referenced in the Analyst Report, involving different adverse events and outcomes.
• Three cases were reported to Agios and the FDA, while one case was reported directly to the FDA.
• One death was reported in the first case, one case involved a patient entering hospice due to kidney failure and cardiac issues, one case involved a patient dying from a pulmonary embolism, and one case involved an adverse event term, including hypertransaminasaemia, with insufficient medical context.

Sources:

• UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
• Analyst Report, published on August 4, 2025, detailing recent PYRUKYND data from the U.S. FDA's Adverse Event Reporting System.